Pseudoephedrine
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Pseudoephedrine: From Rhinitis and the Common Cold to Nasal Cavity Disease
One-Sentence Summary
Pseudoephedrine is a nasal decongestant, originally used for allergic rhinitis, the common cold and related upper airway conditions. The TxGNN model predicts it may be effective for nasal cavity disease, supported by no registered clinical trials and 7 publications (reviews, a comparative pharmacology study and animal models). This prediction largely overlaps with existing uses, so it is not a true repurposing opportunity.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Allergic rhinitis, vasomotor rhinitis, pharyngitis, common cold, nasopharyngitis, conjunctivitis (atopic, papillary, vernal), headache disorder (from the knowledge graph; no approved indication text is available in the Singapore licence records) |
| Predicted New Indication | Nasal cavity disease |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L3 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 20 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, pseudoephedrine is an indirect sympathomimetic with alpha-adrenergic activity. It constricts blood vessels in the nasal mucosa and reduces swelling and congestion. This is the basis of its existing use in rhinitis and the common cold.
"Nasal cavity disease" is a broad category that covers the conditions pseudoephedrine already treats. The supporting literature includes a comparative study of oral and topical decongestant effects (pseudoephedrine versus phenylpropanolamine, measured by acoustic rhinometry), a review of nonallergic rhinitis, and several animal models of nasal congestion. The mechanism fits well, but the new indication adds little beyond what is already established.
Other predictions for this drug (for example acute laryngopharyngitis, allergic urticaria, trigeminal autonomic cephalalgia, rosacea conjunctivitis, cold urticaria, faucial diphtheria, cervical disc degenerative disorder, massive neonatal aspiration syndrome and bronchial disease) have weak or no supporting evidence and are rated Hold or Research Question. Many appear to be artefacts of graph proximity to the approved indications.
Clinical Trial Evidence
Currently no related clinical trials registered for nasal cavity disease.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 22794679 | 2012 | Review | Allergy Asthma Proc | Nonallergic rhinitis: inflammatory and noninflammatory causes, sharing congestion, rhinorrhoea and sneezing |
| 11345158 | 2001 | Clinical pharmacology study | Am J Rhinol | Compared oral and topical decongestant effects of phenylpropanolamine and d-pseudoephedrine on nasal cavity dimensions using acoustic rhinometry |
| 19769798 | 2009 | Preclinical (cat model) | Am J Rhinol Allergy | Loratadine and montelukast combination produced decongestion; d-pseudoephedrine also studied as an alpha-agonist decongestant |
| 24492651 | 2014 | Preclinical (animal models) | J Pharmacol Exp Ther | Selective alpha2c-adrenergic agonists evaluated in nasal congestion models |
| 12962193 | 2003 | Preclinical (dog model) | Am J Rhinol | Model of allergic nasal congestion in ragweed-sensitised dogs, using acoustic rhinometry |
| 12387934 | 2002 | Preclinical (dog model) | J Pharmacol Toxicol Methods | Pharmacological characterisation of a chronic dog model of nasal congestion |
| 11895194 | 2002 | Preclinical (dog model) | Am J Rhinol | Acoustic rhinometry developed as a large-animal model of nasal congestion |
Singapore Market Information
Pseudoephedrine has 20 valid single-ingredient registrations in Singapore, with no cancelled licences. The approved indication text is not available in the licence records. Examples:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN03178P | PSEUDORINE TABLETS 60 mg | Tablet | Not stated in the records |
| SIN09453P | DECONDINE TABLET | Film-coated tablet | Not stated in the records |
| SIN07282P | CLARITYN-D 12HOUR REPETABS | Sugar-coated tablet | Not stated in the records |
| SIN13139P | ZYRTEC-D | Film-coated tablet | Not stated in the records |
| SIN12071P | TELFAST D TABLET | Film-coated tablet | Not stated in the records |
Available forms include tablets, film-coated tablets, sugar-coated tablets, capsules and syrups.
Safety Considerations
- Contraindications flagged in the knowledge graph (not label text): hypertension, coronary artery disease, stroke and cerebrovascular disorder, congestive heart failure, diabetes mellitus and diabetic ketoacidosis, hypothyroidism, benign prostatic hyperplasia, liver and kidney disease, epilepsy, COPD, peptic ulcer disease, inflammatory bowel disease, blood coagulation disease and substance abuse or dependence, among others.
- Drug Interactions: 100 interactions were identified. The ones listed are mostly moderate and involve antidiabetic agents, including acarbose, acetohexamide, alogliptin, canagliflozin, chlorpropamide, dapagliflozin, empagliflozin, exenatide, glimepiride, glipizide, glyburide and several insulins. Diethylpropion (moderate) and ascorbic acid (minor) are also listed.
- Case reports in the literature: posterior reversible encephalopathy syndrome after a pseudoephedrine-containing cold medicine, and myocardial infarction from coronary vasospasm linked to pseudoephedrine use.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The predicted indication, nasal cavity disease, is essentially the same as pseudoephedrine's established use as a nasal decongestant, and the mechanism is well understood. The supplied evidence, however, is limited to reviews, one pharmacology study and animal models, with no registered trials. The cardiovascular and metabolic cautions are significant, so any expansion should be tightly bounded.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Singapore regulator (HSA), since the current safety information comes only from the knowledge graph
- Mechanism of action data from DrugBank
- Approved indication text for the Singapore licences
- Clinical (ideally randomised) evidence for specific nasal conditions beyond those already labelled
- A cardiovascular and drug-interaction risk review for patients with hypertension, heart disease or diabetes
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.